MOG and myeloid sarcoma: Interleukin 17A (IL-17A) and tumor necrosis factor-α (TNF-α), the central mediators of EAE and MS progression29,30, were significantly lower in the MSN-MOG-treated group than in the untreated group (Fig. 2h, i).